臺大學術典藏 |
2020-12-30T02:43:59Z |
Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion
|
Linas M.D.; Sequela J.P.; Mallie M.; Candolfi E.; Ayabaca J.; Dobiasova S.; Hazen K.C.;Baron E.J.;Colombo A.L.;Girmenia C.;Sanchez-Sousa A.;Del Palacio A.;De Bedout C.;Gibbs D.L.;Tiraboschi N.;Finquelievich J.;Ellis D.;Frameree D.;Van Den Abeele A.M.;Rennie R.;Sanche S.;Bijie H.;Xu Y.;Restrepo A.;Vega R.;Mendez M.;Mallatova N.;Dobiasova S.;Ayabaca J.;Mallie M.;Candolfi E.;Sequela J.P.;Linas M.D.;Dupont B.;Braveny I.;Haase G.;Rodloff A.;Bar W.;Gobel U.;Petrikos G.;Puskas E.;Gyula M.;Erzs?Bet N.;Istv?N B.;Korhaz B.;Konkoly-Thege M.;Tullio V.;D'Antonio D.;Scalise G.;Schito G.C.;Fortina G.;Testore G.P.;Eugenio O.S.;Martino P.;Lee K.-W.;Peng N.K.;Zaidi M.;Alpuche C.;Santos J.;Meis J.F.G.M.;Dzierzanowska D.;Stratchounski L.;Langsadl L.;Trupl J.;Vaculikova A.;Helena H.;Roditi D.;Hoosen A.;Van Rensburg J.;Crewe-Brown H.H.;Towindo T.;Garau M.;Alvarez M.E.;Bille J.;Muhlethaler K.;Shan-Chwen Chang;Yu H.-W.;Wang J.-H.;Tharavichitkul P.;Vorachit C.-M.M.;Korten V.;Gur D.;Weightman N.;Gould I.M.;Ashbee R.;Larone D.;Jenkins S.;Chaturvedi V.;Hindler J.;Rinaldi M.;Sobel J.;Ghannoum M.A.;Santiago A.;Global Antifungal Surveillance Group; Hazen K.C.; Baron E.J.; Colombo A.L.; Girmenia C.; Sanchez-Sousa A.; Del Palacio A.; De Bedout C.; Gibbs D.L.; Tiraboschi N.; Finquelievich J.; Ellis D.; Frameree D.; Van Den Abeele A.M.; Rennie R.; Sanche S.; Bijie H.; Xu Y.; Restrepo A.; Vega R.; Mendez M.; Mallatova N.; Van Rensburg J.; Crewe-Brown H.H.; Towindo T.; Garau M.; Alvarez M.E.; Bille J.; Muhlethaler K.; SHAN-CHWEN CHANG; Yu H.-W.; Wang J.-H.; Tharavichitkul P.; Vorachit C.-M.M.; Korten V.; Gur D.; Weightman N.; Gould I.M.; Ashbee R.; Larone D.; Jenkins S.; Chaturvedi V.; Hindler J.; Rinaldi M.; Sobel J.; Ghannoum M.A.; Santiago A.; Global Antifungal Surveillance Group; Dupont B.; Braveny I.; Haase G.; Rodloff A.; Bar W.; Gobel U.; Petrikos G.; Puskas E.; Gyula M.; Erzs?bet N.; Istv?n B.; Korhaz B.; Konkoly-Thege M.; Tullio V.; D'Antonio D.; Scalise G.; Schito G.C.; Fortina G.; Testore G.P.; Eugenio O.S.; Martino P.; Lee K.-W.; Peng N.K.; Zaidi M.; Alpuche C.; Santos J.; Meis J.F.G.M.; Dzierzanowska D.; Stratchounski L.; Langsadl L.; Trupl J.; Vaculikova A.; Helena H.; Roditi D.; Hoosen A. |
臺大學術典藏 |
2020-05-26T09:26:46Z |
134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)
|
Mitsudomi T.;J?nne P;Cantarini M;Lawrance R;Weston S;Patel S;Yu K;Ramalingam S;Chih-Hsin Yang;Jenkins S; Jenkins S; CHIH-HSIN YANG; Ramalingam S; Yu K; Patel S; Weston S; Lawrance R; Cantarini M; Jänne P; Mitsudomi T. |
臺大學術典藏 |
2020-05-26T09:26:46Z |
134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)
|
Mitsudomi T.;J?nne P;Cantarini M;Lawrance R;Weston S;Patel S;Yu K;Ramalingam S;Chih-Hsin Yang;Jenkins S; Jenkins S; CHIH-HSIN YANG; Ramalingam S; Yu K; Patel S; Weston S; Lawrance R; Cantarini M; Jänne P; Mitsudomi T. |
臺大學術典藏 |
2020-05-26T09:26:37Z |
Plasma ctDNA Analysis for Detection of the EGFR?T790M Mutation in Patients with Advanced Non?�Small?Cell Lung Cancer
|
Goss G.D.;Mitsudomi T;J?nne P.A;Cantarini M;Hodge R;Weston S;Patel S;Yu K;Ramalingam S.S;Chih-Hsin Yang;Jenkins S; Jenkins S; CHIH-HSIN YANG; Ramalingam S.S; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne P.A; Mitsudomi T; Goss G.D. |
臺大學術典藏 |
2020-05-26T09:26:37Z |
Plasma ctDNA Analysis for Detection of the EGFR?T790M Mutation in Patients with Advanced Non?�Small?Cell Lung Cancer
|
Goss G.D.;Mitsudomi T;J?nne P.A;Cantarini M;Hodge R;Weston S;Patel S;Yu K;Ramalingam S.S;Chih-Hsin Yang;Jenkins S; Jenkins S; CHIH-HSIN YANG; Ramalingam S.S; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne P.A; Mitsudomi T; Goss G.D. |
臺大學術典藏 |
2020-05-26T09:26:37Z |
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
|
Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A. |
臺大學術典藏 |
2020-05-26T09:26:37Z |
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
|
Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A. |
國立成功大學 |
2019 |
Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non–small cell lung cancer
|
Gray, J.E.;Okamoto, I.;Sriuranpong, V.;Vansteenkiste, J.;Imamura, F.;Lee, J.S.;Pang, Y.-K.;Cobo, M.;Kasahara, Kasahara K.;Cheng, Y.;Nogami, Nogami N.;Cho, E.K.;Su, W.C.;Zhang, G.;Huang, X.;Li-Sucholeiki, X.;Lentrichia, B.;Dearden, S.;Jenkins, S.;Saggese, M.;Rukazenkov, Y.;Ramalingam, S.S. |
國立成功大學 |
2018 |
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer
|
John, T.;Akamatsu, H.;Delmonte, A.;Su, W.-C.;Lee, J.S.;Chang, G.-C.;Huang, X.;Jenkins, S.;Wu, Y.-L. |